The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma – Cancer Therapy Advisor
Cancer Therapy Advisor |
The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma
Cancer Therapy Advisor It is not always clear whether patients who discontinue anti-PD-1 and -CTLA-4 therapy should re-initiate treatment after adverse events are resolved. Immune checkpoint inhibitors targeting CLTA-4 and PD-1 are dramatically improving survival rates among … |
